Interventions of interest, July 2014 review:

  • OnabotulinumtoxinA (Botox®, Allergan, Inc)
  • Transcutaneous electrical nerve stimulation (Cefaly®, Cefaly Technology)
  • Single pulse transcranial magnetic stimulation (SpringTMS™, eNeura Inc.)

Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or to sound), have a reduced ability to function, or require bed rest. Despite its high prevalence and impairment, migraine is often not recognized or effectively treated.

For questions or additional information, please contact info@icer.org.

Final Documents

Below you will find the final documents from the assessment review process:

Public CommentsDownload
Final Evidence Report and Meeting SummaryDownload